arrow_back Back to App

Extending Price Protection for New Gene Therapy Drugs.

This bill extends the period during which certain highly innovative, genetically targeted drugs are shielded from specific government price negotiations. The protection period for these 'advanced drug products' is increased from 7 years to 11 years. This aims to incentivize pharmaceutical companies to develop complex gene therapies, but it means these expensive treatments will remain outside of potential price controls for an additional four years.
Key points
Extends the protection period from 7 to 11 years for drugs utilizing genetically targeted technologies (gene therapies).
The change is intended to encourage continued investment in the research and development of advanced medical treatments.
The consequence is that these high-cost drugs will maintain their price for four additional years before government programs can negotiate their cost.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_476
Sponsor: Sen. Menendez, Robert [D-NJ]
Process start date: 2023-02-16
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Maintaining Investments in New Innovation Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_476.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-02-16.

What are the main provisions?

Key points include:

  • Extends the protection period from 7 to 11 years for drugs utilizing genetically targeted technologies (gene therapies).
  • The change is intended to encourage continued investment in the research and development of advanced medical treatments.
  • The consequence is that these high-cost drugs will maintain their price for four additional years before government programs can negotiate their cost.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Menendez, Robert [D-NJ].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health